179 related articles for article (PubMed ID: 35947299)
1. Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency.
Ceccato F; Torchio M; Tizianel I; Peleg Falb M; Barbot M; Sabbadin C; Betterle C; Scaroni C
J Endocrinol Invest; 2023 Jan; 46(1):111-122. PubMed ID: 35947299
[TBL] [Abstract][Full Text] [Related]
2. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency.
Flad TM; Conway JD; Cunningham SK; McKenna TJ
Clin Endocrinol (Oxf); 1996 Nov; 45(5):529-34. PubMed ID: 8977748
[TBL] [Abstract][Full Text] [Related]
3. Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone.
Baumstark ME; Nussberger J; Boretti FS; Baumstark MW; Riond B; Reusch CE; Sieber-Ruckstuhl NS
J Vet Intern Med; 2014; 28(5):1471-8. PubMed ID: 25274440
[TBL] [Abstract][Full Text] [Related]
4. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.
Cohen N; Gilbert R; Wirth A; Casley D; Jerums G
J Clin Endocrinol Metab; 1996 Apr; 81(4):1411-5. PubMed ID: 8636343
[TBL] [Abstract][Full Text] [Related]
5. Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency.
Pofi R; Prete A; Thornton-Jones V; Bryce J; Ali SR; Faisal Ahmed S; Balsamo A; Baronio F; Cannuccia A; Guven A; Guran T; Darendeliler F; Higham C; Bonfig W; de Vries L; Bachega TASS; Miranda MC; Mendonca BB; Iotova V; Korbonits M; Krone NP; Krone R; Lenzi A; Arlt W; Ross RJ; Isidori AM; Tomlinson JW
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31613957
[TBL] [Abstract][Full Text] [Related]
6. Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy.
Esposito D; Pasquali D; Johannsson G
J Clin Endocrinol Metab; 2018 Feb; 103(2):376-387. PubMed ID: 29156052
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid substitution and monitoring in primary adrenal insufficiency.
Quinkler M; Oelkers W; Remde H; Allolio B
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):17-24. PubMed ID: 25617169
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.
Oelkers W; Diederich S; Bähr V
J Clin Endocrinol Metab; 1992 Jul; 75(1):259-64. PubMed ID: 1320051
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid replacement in Addison's disease.
Thompson DG; Mason AS; Goodwin FJ
Clin Endocrinol (Oxf); 1979 May; 10(5):499-506. PubMed ID: 476980
[TBL] [Abstract][Full Text] [Related]
10. Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.
Pofi R; Bonaventura I; Duffy J; Maunsell Z; Shine B; Isidori AM; Tomlinson JW
Endocr Connect; 2023 Aug; 12(9):. PubMed ID: 37410094
[TBL] [Abstract][Full Text] [Related]
11. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement.
Oelkers W; L'age M
Klin Wochenschr; 1976 Jul; 54(13):607-12. PubMed ID: 940296
[TBL] [Abstract][Full Text] [Related]
12. Evidence that patients with Addison's disease are undertreated with fludrocortisone.
Smith SJ; MacGregor GA; Markandu ND; Bayliss J; Banks RA; Prentice MG; Dorrington-Ward P; Wise P
Lancet; 1984 Jan; 1(8367):11-4. PubMed ID: 6140341
[TBL] [Abstract][Full Text] [Related]
13. The acute effect of a mineralocorticoid receptor agonist on corticotrope secretion in Addison's disease.
Berardelli R; Karamouzis I; D'Angelo V; Fussotto B; Minetto MA; Ghigo E; Giordano R; Arvat E
J Endocrinol Invest; 2016 May; 39(5):537-42. PubMed ID: 26450146
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age.
Bonfig W; Schwarz HP
Clin Endocrinol (Oxf); 2014 Dec; 81(6):871-5. PubMed ID: 24818525
[TBL] [Abstract][Full Text] [Related]
15. Stress-Dosed Glucocorticoids and Mineralocorticoids Before Intensive Endurance Exercise in Primary Adrenal Insufficiency.
Bonnecaze AK; Reynolds P; Burns CA
Clin J Sport Med; 2019 Nov; 29(6):e73-e75. PubMed ID: 31688185
[TBL] [Abstract][Full Text] [Related]
16. Performance of renin assays in selecting fludrocortisone dose in children with adrenal disorders.
Morris TJ; Whatmore A; Hamilton L; Hird B; Kilpatrick ES; Tetlow L; Clayton P
Endocr Connect; 2024 Feb; 13(2):. PubMed ID: 38165389
[TBL] [Abstract][Full Text] [Related]
17. Management of adrenal insufficiency in different clinical settings.
Hahner S; Allolio B
Expert Opin Pharmacother; 2005 Nov; 6(14):2407-17. PubMed ID: 16259572
[TBL] [Abstract][Full Text] [Related]
18. Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Irony I; Cutler GB
Clin Endocrinol (Oxf); 1999 Sep; 51(3):285-91. PubMed ID: 10469007
[TBL] [Abstract][Full Text] [Related]
19. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention.
Krishna GG; Kapoor SC
Kidney Int; 1993 May; 43(5):1097-103. PubMed ID: 8510388
[TBL] [Abstract][Full Text] [Related]
20. [Fludrocortisone substitution in adrenal cortex insufficiency].
Jungmann E; Althoff PH; Schöffling K
Dtsch Med Wochenschr; 1985 May; 110(21):850-1. PubMed ID: 3888590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
